Skip to content
Luna Metabolic
Menu

We earn commissions; partners may appear first. Disclosure

Women's-health guide

Does Ozempic Affect Your Period? GLP-1s, Your Cycle and Hormones

Period changes on Ozempic, Wegovy and Zepbound: why cycles often come back, what heavier or irregular bleeding may mean, the pill caution, and libido.

By Luna Editorial Team, PublisherUpdated
On this page

Featured partner

Grade A
CoreAge Rx logo

CoreAge Rx

93/100

Compounded semaglutide and tirzepatide on one account, at one posted price that does not rise with your dose — tirzepatide being the option many women with insulin resistance ask about.

Check availability
Semaglutide
Starting at $79/mo
Tirzepatide
Starting at $129/mo
Full review →Ad disclosure — we may earn a commission.
Partner
MEDGm logo

MEDGm

Grade C

Names four possible dispensing pharmacies and describes portal care, but current public pages do not establish a complete renewal quote.

Visit MEDGm

It can. The most common change is a good one for many women: as weight and insulin levels fall, periods that were irregular or absent often become regular again, especially with PCOS, and ovulation comes back with them67. That also means you can get pregnant sooner than expected. Some women report heavier periods, clots or spotting between periods; reports to the FDA describe these more often than expected for semaglutide (Ozempic, Wegovy) and, for spotting and clots, tirzepatide (Zepbound, Mounjaro), though reports alone cannot prove the drug caused them5. A late period on a GLP-1 calls for a pregnancy test first.

Does Ozempic affect your period?

There are no large trials that tracked periods as an outcome, so the picture comes from three sources: studies in women with PCOS, reports sent to the FDA, and what is known about weight loss and the cycle.

Studies in PCOS show the clearest effect. In women with PCOS who took low-dose semaglutide, cycles normalized in 80% of those who lost at least 5% of their weight6. In a larger group of 96 women, ovulation returned in just over half of those who had not been ovulating7. In a randomized trial that added semaglutide to metformin, more women recovered regular cycles than on metformin alone, and more became pregnant in the months after8.

FDA reports suggest other changes. A 2026 analysis of the FDA's adverse event reporting system, limited to women aged 12 to 55, found semaglutide was reported more often than expected with heavy menstrual bleeding, bleeding between periods, menstrual clots, infrequent periods and cycles without ovulation. Tirzepatide was reported more often with bleeding between periods and clots. Liraglutide, an older GLP-1, showed no signal5. These are voluntary reports, not a controlled comparison, so they flag patterns worth asking about rather than prove a cause. The authors' own conclusion was that menstrual health should be part of counseling for women of reproductive age.

Body fat and exercise matter too. Very low body fat or intense exercise can stop periods altogether, which is one of the causes clinicians rule out when periods disappear9.

What period changes might you notice on a GLP-1?

Swipe or scroll to compare →
What you noticeWhat may be behind itWhat to do
Periods return or become regularOvulation coming back as weight and insulin fall, most often with PCOSUse reliable contraception if you do not want a pregnancy
Late or missed periodPregnancy first; also reported on semaglutide; very low body fat or hard trainingTake a pregnancy test before anything else
Heavier periods or clotsReported more often than expected on semaglutide and tirzepatide; cause unprovenTrack cycles and tell your clinician
Spotting between periodsReported more often than expected on both drugsMention it, especially if it persists
Irregular bleeding in your 40sOften the perimenopause transition itselfAny bleeding after menopause needs prompt checking

Heavy bleeding that soaks through a pad or tampon every hour for several hours, or bleeding with dizziness or fainting, needs urgent care whatever its cause. Iron also runs down faster with heavier periods while you are eating less, which is one reason our labs guide suggests a ferritin check.

When does ovulation come back, and why does it matter?

Losing weight and improving insulin sensitivity can restore more regular ovulation, particularly in women with PCOS. That is usually welcome, but it also means fertility can increase unexpectedly on treatment4. In the semaglutide PCOS studies, the cycle changes showed up within six months of starting67, so ovulation can return before you have finished titrating. A missed period that you would once have put down to PCOS may now be a pregnancy.

Because GLP-1 medicines are not appropriate during pregnancy, reliable contraception during treatment, and a plan to stop well before trying to conceive, is part of using them responsibly. The Wegovy label advises stopping at least 2 months before a planned pregnancy1. The 2023 international PCOS guideline asks clinicians to make sure effective contraception is in place whenever pregnancy is possible on a GLP-1, because pregnancy safety data are lacking9. Our guide to fertility and pregnancy on a GLP-1 covers stopping times for each drug, and if you are planning IVF, see GLP-1 before IVF and fertility treatment. For the PCOS side of the story, see our PCOS guide.

Do GLP-1s change your other hormones?

The hormone change with the best evidence is in androgens, the "male" hormones that run high in many women with PCOS and drive acne, excess hair and irregular cycles. In a placebo-controlled trial of liraglutide in women with PCOS, the free androgen index, a measure of active testosterone, fell on the drug and rose slightly on placebo over 32 weeks13. In the trial that added semaglutide to metformin, testosterone fell more than on metformin alone8. Lower insulin is the likely link, since excess insulin pushes the ovaries to make more androgen4.

These are hormone changes that come with treating the metabolic problem, not hormone therapy. A GLP-1 does not replace estrogen or progesterone, and it is not a contraceptive, even though it can make your cycle more regular. If you are using hormone therapy for menopause symptoms, keep that conversation separate, and see the perimenopause section below.

Birth control: a caution worth taking seriously

This is the single women's-health point most often missed. Tirzepatide can reduce the effectiveness of oral contraceptives, and its labeling advises women using the pill to switch to a non-oral method or add a barrier method for 4 weeks after starting and for 4 weeks after each dose increase2. The mechanism, slowed gastric emptying affecting absorption, is exactly why it matters most when your dose is changing. If you rely on the pill, raise this with your provider before your first injection, not after. Our full guide to GLP-1s and birth control breaks down why tirzepatide and semaglutide differ here and which methods are unaffected.

Does your cycle change how a GLP-1 feels?

Many women notice that appetite and cravings already fluctuate across the menstrual cycle; GLP-1 medicines act on the same appetite pathways, and some women report that nausea or fullness feels more pronounced at certain points in their cycle. There is limited formal research here, so it is best treated as something to track and discuss rather than a fixed rule. The only direct evidence so far is in animals: in female rats, liraglutide and semaglutide suppressed eating more, and semaglutide produced more weight loss, when given during one phase of the reproductive cycle than another10. Whether that carries over to women is unknown, and no one should time doses by cycle phase on the strength of a rat study.

The larger trials establish the overall efficacy and side-effect profile of these drugs across mixed populations3. Our guide to GLP-1 side effects in women covers the rest. Headaches that cluster around your cycle are worth separating from a different, less commonly discussed pattern: migraine and a related condition, idiopathic intracranial hypertension, both skew heavily female and both show real early evidence of responding to GLP-1 treatment directly, not just through weight loss, covered in our guide to GLP-1, migraine and intracranial hypertension in women.

Does Ozempic affect libido or sex drive?

The honest answer is that nobody knows yet. A 2026 review from Mayo Clinic researchers, published in the journal of The Menopause Society, found the effects of GLP-1 medicines on women's sexual function "largely uncharacterized." Weight loss through lifestyle change or surgery tends to improve sexual function, but GLP-1 drugs may also dampen desire through their effects on the brain's reward pathways, a concern so far supported by case reports and animal studies rather than trials11. A second review found human evidence mixed: FDA reports mention reduced libido, but without a clear statistical signal, and users online describe both better and worse desire, the better often tied to improved body image12.

The Mayo review urges clinicians to ask about sexual function before and during treatment. If your sex drive changes, say so: it is a fair thing to raise with your clinician, and it may have other causes worth checking, from mood to the menopause transition.

What about perimenopause and HRT?

If you are in your 40s, irregular bleeding is often the menopause transition rather than the medicine, and the two can overlap. Bleeding after menopause, meaning after 12 months without a period, always needs prompt checking. Many women in this stage also use hormone therapy alongside a GLP-1; our guides to GLP-1s in perimenopause and menopause and whether HRT causes weight gain cover how the two fit together.

Bring these questions to a provider

A provider that understands women's health should be able to talk through contraception, pregnancy planning, and how your cycle interacts with dosing, not just hand over a prescription. Useful questions:

  • Which contraception works with the drug you are prescribing, and for how long around dose increases?
  • What should I do if my period is late, much heavier or keeps spotting?
  • How long before trying to conceive should I stop?
  • Which labs will you check before I start and a few months in, and will that include iron if my periods are heavy?
  • If I am in perimenopause, how will you tell a side effect from the transition itself?

That kind of oversight is what our Luna Fit Score rewards; see the Luna Fit Score methodology and our women's-health evidence library. This guide is educational only and is not medical advice. Talk to a licensed clinician before starting any treatment.

Frequently asked questions

Can a GLP-1 medicine make my birth control pill fail?

Tirzepatide's labeling warns it can reduce oral contraceptive effectiveness, especially around starting and dose increases, and advises a non-oral or barrier method for 4 weeks after starting and after each dose increase. Discuss your contraception with your provider before starting.

Do I need to stop before trying to get pregnant?

Yes. GLP-1 medicines are not used in pregnancy, and the Wegovy label advises stopping at least 2 months before a planned pregnancy. Because treatment can also restore ovulation, plan contraception and timing with your clinician.

Can Ozempic make your period late?

Infrequent periods have been reported to the FDA more often than expected with semaglutide. But GLP-1s can also bring ovulation back, so a late period on treatment should prompt a pregnancy test first.

Can Ozempic or Zepbound cause heavy periods?

Heavy bleeding and clots have been reported to the FDA more often than expected with semaglutide, and clots and spotting with tirzepatide. Reports cannot prove the drug was the cause. Track your cycles and tell your clinician; very heavy bleeding or bleeding with dizziness needs urgent care.

References

  1. U.S. Food and Drug Administration (2023). Wegovy (semaglutide) injection — prescribing information. FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf
  2. U.S. Food and Drug Administration (2022). Mounjaro (tirzepatide) injection — prescribing information (oral contraceptive caution). FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf
  3. Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2206038
  4. American College of Obstetricians and Gynecologists (2023). Polycystic Ovary Syndrome (PCOS): patient FAQ. ACOG. https://www.acog.org/womens-health/faqs/polycystic-ovary-syndrome-pcos
  5. Frey C, Etminan M (2026). Association of Glucagon-Like Peptide-1 Receptor Agonists With Menstrual Events in Reproductive-Aged Patients. Obstetrics & Gynecology. https://doi.org/10.1097/AOG.0000000000006367
  6. Carmina E, Longo RA (2023). Semaglutide Treatment of Excessive Body Weight in Obese PCOS Patients Unresponsive to Lifestyle Programs. Journal of Clinical Medicine. https://doi.org/10.3390/jcm12185921
  7. Carmina E, Longo RA (2026). Evidence That Semaglutide Represents an Important Tool for Treatment of Irregular Menses and Chronic Anovulation in Women with Polyendocrine Metabolic Ovarian Syndrome. Journal of Clinical Medicine. https://doi.org/10.3390/jcm15135165
  8. Chen H, Lei X, Yang Z, et al. (2025). Effects of combined metformin and semaglutide therapy on body weight, metabolic parameters, and reproductive outcomes in overweight/obese women with polycystic ovary syndrome: a prospective, randomized, controlled, open-label clinical trial. Reproductive Biology and Endocrinology. https://doi.org/10.1186/s12958-025-01447-3
  9. Teede HJ, Tay CT, Laven JJE, et al. (2023). Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgad463
  10. Applebey SV, Xiao AG, Reiner BC, Hayes MR (2026). The estrous cycle moderates the food and body weight suppressive effects of glucagon-like peptide-1 receptor agonism. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70177
  11. Castaneda R, Sepulveda D, Hurtado Andrade MD, Shufelt CL, Faubion SS (2026). Weight loss interventions and sexual function in midlife women: the emerging role of glucagon-like peptide-1 receptor agonists. Menopause. https://doi.org/10.1097/GME.0000000000002854
  12. Merhi Z (2026). GLP-1 receptor agonists and sexual function in women and men: a narrative review of emerging evidence and the need for further research. Sexual Medicine Reviews. https://doi.org/10.1093/sxmrev/qeag015
  13. Elkind-Hirsch KE, Chappell N, Shaler D, et al. (2022). Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized placebo-controlled-phase 3 study. Fertility and Sterility. https://doi.org/10.1016/j.fertnstert.2022.04.027

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.